CytoMed Therapeutics Limited (GDTC)

CytoMed Therapeutics Income Statement

Financials in millions SGD. Fiscal year is January - December.

Year	2023	2022	2021	2020
Selling, General & Admin	0.45	0.21	0.17	0.13
Research & Development	1.59	1.52	1.09	1.04
Other Operating Expenses	-0.21	0.74	-0.06	0.53
Operating Expenses	1.84	2.48	1.2	1.7
Operating Income	-1.84	-2.48	-1.2	-1.7
Interest Expense / Income	0.05	0.13	0.12	0.11
Other Expense / Income	2.24	0.53	0.73	0.13
Pretax Income	-4.13	-3.13	-2.05	-1.94
Income Tax	0	0	0	0
Net Income	-4.13	-3.13	-2.05	-1.94
Shares Outstanding (Basic)	11	8	7	6
Shares Outstanding (Diluted)	11	8	7	6
Shares Change	34.30%	14.14%	17.59%	-
EPS (Basic)	-0.39	-0.40	-0.30	-0.33
EPS (Diluted)	-0.39	-0.40	-0.30	-0.33
Free Cash Flow	-3.59	-1.87	-2.3	-1.09
Free Cash Flow Per Share	-0.34	-0.24	-0.33	-0.19
EBITDA	-3.7	-2.61	-1.6	-1.54
Depreciation & Amortization	0.38	0.39	0.33	0.29
EBIT	-4.08	-3	-1.93	-1.83

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).